Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
149.52
+3.19 (2.18%)
At close: Oct 30, 2026, 4:00 PM EDT
149.55
+0.03 (0.02%)
After-hours: Oct 30, 2026, 7:59 PM EDT
Merck & Co. Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 67,378 | 65,011 | 64,168 | 60,115 | 59,283 | 48,704 |
Revenue Growth | 4.89% | 1.31% | 6.74% | 1.40% | 21.72% | 17.31% |
Gross Profit Gross Profit Growth | 51,822 | 50,196 | 49,470 | 44,200 | 42,077 | 35,238 |
Operating Income Operating Income Growth | 10,142 | 24,467 | 24,889 | 15,974 | 20,490 | 13,893 |
Net Income Net Income Growth | 2,453 | 18,254 | 17,117 | 365 | 14,519 | 13,049 |
Earnings Per Share EPS Growth | 0.99 | 7.28 | 6.74 | 0.14 | 5.71 | 5.14 |
EPS Growth | -86.93% | 8.01% | 4714.29% | -97.55% | 11.15% | 84.61% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Keytruda/Keytruda Qlex Keytruda/Keytruda Qlex Growth | 33,373 | 31,681 | 29,482 | 25,011 | 20,937 | 17,186 |
Gardasil/Gardasil 9 Gardasil/Gardasil 9 Growth | 5,264 | 5,233 | 8,583 | 8,886 | 6,897 | 5,673 |
Januvia/Janumet Januvia/Janumet Growth | 1,884 | 2,544 | 2,268 | 3,366 | 4,513 | 5,288 |
ProQuad/M-M-R II/Varivax ProQuad/M-M-R II/Varivax Growth | 2,479 | 2,451 | 2,485 | 2,368 | 2,241 | 2,135 |
Bridion Bridion Growth | 1,612 | 1,841 | 1,764 | 1,842 | 1,685 | 1,532 |
Lynparza - Alliance Lynparza - Alliance Growth | 1,447 | 1,450 | 1,311 | 1,199 | 1,116 | 989 |
Winrevair Winrevair Growth | 2,274 | 1,443 | 419 | - | - | - |
Lenvima - Alliance Lenvima - Alliance Growth | 1,098 | 1,053 | 1,010 | 960 | 876 | 704 |
Animal Health Animal Health Growth | 6,747 | 6,354 | 5,877 | 5,625 | 5,550 | 5,568 |
Other Product Other Product Growth | 411 | 515 | 891 | 907 | 1,728 | 382 |
Other Other Growth | 10,789 | 10,446 | 10,078 | 9,951 | 13,740 | 9,247 |
Revenue (Total) Revenue (Total) Growth | 67,378 | 65,011 | 64,168 | 60,115 | 59,283 | 48,704 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 7,141 | 14,565 | 13,689 | 7,093 | 13,192 | 8,096 |
Total Debt Total Debt Growth | 53,911 | 50,534 | 38,270 | 36,268 | 31,985 | 34,631 |
Net Cash (Debt) Net Cash Growth | -46,770 | -35,969 | -24,581 | -29,175 | -18,793 | -26,535 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -18.90 | -14.35 | -9.67 | -11.45 | -7.39 | -10.46 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | - | 16,472 | 21,468 | 13,006 | 19,095 | 14,109 |
Capital Expenditures CapEx Growth | - | -4,112 | -3,372 | -3,863 | -4,388 | -4,448 |
Free Cash Flow Free Cash Flow Growth | - | 12,360 | 18,096 | 9,143 | 14,707 | 9,661 |
Free Cash Flow Growth | - | -31.70% | 97.92% | -37.83% | 52.23% | 66.22% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 76.91% | 77.21% | 77.09% | 73.53% | 70.98% | 72.35% |
Operating Margin | 15.05% | 37.64% | 38.79% | 26.57% | 34.56% | 28.52% |
Pretax Margin | 7.07% | 32.41% | 31.07% | 3.14% | 27.74% | 28.50% |
Profit Margin | 3.64% | 28.08% | 26.67% | 0.61% | 24.49% | 26.79% |
FCF Margin | - | 19.01% | 28.20% | 15.21% | 24.81% | 19.84% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 3.400 | 3.240 | 3.080 | 2.920 | 2.760 | 2.600 |
Dividend Per Share Growth | 4.94% | 5.20% | 5.48% | 5.80% | 6.15% | 6.56% |
Dividend Yield | 2.27% | 3.07% | 3.09% | 2.68% | 2.49% | 3.40% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 151.22 | 14.31 | 14.70 | 756.88 | 19.38 | 14.84 |
Forward PE | 17.38 | 12.18 | 11.05 | 17.47 | 15.45 | 10.97 |
P/FCF Ratio | 22.97 | 21.14 | 13.91 | 30.22 | 19.13 | 20.04 |
PS Ratio | 5.47 | 4.02 | 3.92 | 4.60 | 4.75 | 3.98 |